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Abstract  
 
 Cells have a number of mechanisms to maintain protein homeostasis, including proteasome-
mediated degradation of ubiquitinated proteins DQGDXWRSKDJ\DUHJXODWHGSURFHVVRIµVHOI-HDWLQJ¶ZKHUH
the contents of entire organelles can be recycled for other uses. The unfolded protein response prevents 
protein overload in the secretory pathway. In the past decade, it has become clear that these fundamental 
cellular processes also help contain inflammation though degrading pro-inflammatory protein complexes 
such as the NLRP3 inflammasome. Signaling pathways such as the UPR can also be co-opted by toll-
like receptor and mitochondrial reactive oxygen species signaling to induce inflammatory responses. 
Mutations that alter key inflammatory proteins, such as NLRP3 or TNFR1, can overcome normal 
protein homeostasis mechanisms, resulting in autoinflammatory diseases. Conversely, Mendelian 
defects in the proteasome cause protein accumulation, which can trigger interferon-dependent 
autoinflammatory disease. In non-Mendelian inflammatory diseases, polymorphisms in genes affecting 
the UPR or autophagy pathways can contribute to disease, and in diseases not formerly considered 
inflammatory such as neurodegenerative conditions and type 2 diabetes, there is increasing evidence that 
cell intrinsic or environmental alterations in protein homeostasis may contribute to pathogenesis. 
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Cells must maintain a delicate balance between the demands for protein synthesis and the need to 
avoid accumulation of incompletely processed or unfolded proteins that can accumulate under normal 
conditions and even more so when cells face a variety of stresses. The unfolded protein response (UPR) 
is an evolutionarily conserved mechanism to maintain cellular homeostasis by preventing the 
accumulation of misfolded proteins in the endoplasmic reticulum (ER). Disturbed protein folding in the 
ER is primarily detected by three transmembrane (TM) proteins: activating transcription factor 6 
(ATF6), inositol-requiring transmembrane kinase/endonuclease 1 (IRE1) and pancreatic ER kinase 
(PERK). The combined action of these sensors reduces global protein synthesis while upregulating the 
production of chaperone proteins that can stabilize misfolded proteins. Apart from ER homeostasis, the 
UPR can modulate other biological functions, including apoptosis, protein secretion, and as we will 
discuss further, inflammatory responses [1, 2].  
     
A series of molecular changes are initiated in response to cellular stressors in order to minimize 
damage caused by unfavorable environmental conditions, such as temperature changes, toxins (e.g. 
bacterial, chemical), radiation, mechanical damage, nutritional status as well as incompletely folded 
proteins intracellularly (Figure 1). The UPR serves the adaptive purpose of protecting the cell by 
activating a series of mechanisms including the induction of molecular chaperones to assist with correct 
folding - e.g. heat shock proteins and foldases. Interestingly there are a number of connections between 
the UPR and inflammatory signaling pathways. IRE-1 initiates a transcriptional response to ER stress 
through triggering alternative splicing of the mRNA encoding the XBP-1 bZIP-family transcription 
factor, to remove a 26 nucleotide unconventional intron and allow translation of the functional 
transcription factor. Independently of XBP-1, IRE1 can also activate the JNK kinase pathway, a well-
known mediator of cellular stress that can activate pro-inflammatory gene transcription [3]. Partial 
activation of the UPR mediated by IRE1 can also be triggered by activation of the innate immune 
receptors, toll-like receptor (TLR) 2 and TLR4, which results in activation of pro-inflammatory genes. 
When all reparative UPR mechanisms are overcome, apoptosis can be triggered through PERK and 
ATF6, which may dampen the inflammatory response to cells dying due to overload of misfolded 
proteins.  
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The major degradation mechanisms for misfolded/unfolded proteins outside the secretory 
pathway include the ubiquitin-proteasome and autophagy-lysosome systems. Addition of K48-linked 
polyubiquitin tags proteins for rapid elimination by the proteasome. Autophagy involves encapsulation 
of protein aggregates and organelles within double membrane structures called autophagosomes. 
Autophagosomes fuse with lysosomes resulting in the degradation of their cargo. A number of 
abnormalities of the UPR, proteasome and autophagy-lysosome pathways have been implicated in the 
pathogenesis of several diseases, including neurodegenerative and cardiovascular disease [4, 5]. In this 
review, we will discuss the role of misfolded proteins and altered protein homeostasis in 
autoinflammatory diseases, which has emerged as a theme in the pathogenesis of these diseases over the 
last few years [6]. 
 
Autoinflamamatory diseases linked to disorders in protein misfolding 
 
Autoinflammatory disease is defined as self-directed inflammation distinguishable from 
autoimmune disease by the absence of high-titer autoantibodies or antigen-specific T cells and 
involvement of tissue-specific factors [7]. Although originally conceptualized as distinct disease states 
of aberrant innate and adaptive immunity respectively, it is now widely accepted that the two categories 
exist along a continuum, with monogenic autoinflammatory and autoimmune diseases at opposite 
extremes of the spectrum [8]. Various pathological mechanisms are implicated in the monogenic 
autoimmune diseases described to date, including inappropriate inflammasome activation, proteasome 
deficiency, generation of harmful reactive oxygen species (ROS), and, more recently, the UPR and 
autophagy processes [9]. These latter inter-connected cellular environmental responses are currently 
only described in a select number of autoinflammatory diseases (table 1), the most notable being tumor 
necrosis factor (TNF) receptor associated periodic fever syndrome (TRAPS). 
 
TRAPS is an autosomal dominant monogenic autoinflammatory disease characterized by 
periodic fevers, abdominal pain, arthralgia, myalgia, migratory dermatitis, periorbital edema and raised 
inflammatory markers, due to loss of function mutations in the TNF receptor 1 (TNFR1) gene located on 
Ch12p13.31[9-11]. The TNFR1 is a homotrimeric receptor complex composed of an extracellular 
binding domain comprised of 4 cysteine-rich domains (CRDs), a transmembrane domain, and an 
intracellular death domain [9]. Currently 141 TNFR1 mutations are registered on the INFEVERS 
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database for TRAPS, most being missense mutations affecting exons 2-4 which form the CRDs [12]. 
TRAPS disease-causing mutations are clinically heterogeneous. Mutations in the CRDs are often 
associated with severe disease, such as the T50M and C88R mutations, whereas other mutations may be 
less severe; for example, R92Q and P46L variants may be associated with mild disease or can be 
clinically asymptomatic, and have a 1-5% prevalence in the population [13]. Although the inflammatory 
features of disease suggests that TRAPS-linked TNFR1 mutations should be gain-of-function, knock-in 
mice homozygous for TRAPS mutations do not manifest a TRAPS disease phenotype, but are resistant 
to LPS-induced septic shock [14]. In keeping with these reports the majority of TRAPS-causing 
mutations observed to date are heterozygous, suggesting that expression of both the functional and 
mutant receptor is required for TRAPS pathogenesis [9].  
 
There are a number of mechanisms by which the mutated TNFR1 may lead to inflammatory 
disease [9, 13]. The TNFR1 is present physiologically in both the soluble (sTNFR1) and membrane 
(mTNFR1) bound form, both of which are decreased in TRAPS patients [15-20]. These observations 
suggest either defective receptor shedding or defective trafficking of mutant receptors to the cell surface. 
Most probably the latter mechanism plays a significant role in TRAPS pathogenesis, given that 
accumulation  of mutant TNFR1 can be found in the  ER of mutant TNFR1 transfected cell lines 
associated with increased ER stress [20]. It has been postulated that TNF release stimulated by UPR 
activation may then signal through the wild-type TNFR1, generating an autocrine positive feedback loop 
enhancing TNF production [21, 22]. It is also conceivable that mutant intracellular TNFR1 may still 
stimulate TNF production by activation of their intracellular death domains independent of receptor-
ligand binding, particularly as this domain is rarely mutated in TRAPS. However, clear evidence for 
such a mechanism is lacking [18]. 
 
Upregulation of UPR response genes has been reported in TRAPS patients. A study of 16 
TRAPS patients with different mutations, 22 healthy controls (HC) and HEK293 wild type and mutant 
transfectants, detected increased splicing of X-box binding protein 1 (sXBP1), a key UPR transcription 
factor, alongside increased protein kinase (PKR)-like endoplasmic reticulum kinase (PERK) 
phosphorylation in TRAPS patient monocytes and in HEK293 mutants compared with HC and wild type 
HEK293 cells [23]. Intriguingly, 6 other UPR genes tested were not differentially up-regulated and 
activation of UPR genes downstream of sXBP1 was not observed between TRAPS and peripheral blood 
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mononuclear cells (PMBCs) from human controls. Instead, the authors proposed a mechanism of non-
canonical XBP1 splicing induced by lipopolysaccharide (LPS) ligand acting on its receptor, TLR4, and 
TRAPS monocytes are hyper-responsive to LPS. These results are consistent with previous studies 
which identify a role for sXBP1 in TLR responses [24].  Interestingly, XBP1 binding sites were also 
identified in the TNF and IL-6 gene promoters [24]; thus, XBP1 in TRAPS could also contribute to pro-
inflammatory cytokine production independent of canonical UPR pathways 
 
Oxidative stress has also emerged as another trigger of enhanced inflammatory responses in 
TRAPS. Increased IL-6 production in response to LPS stimulation in cells with TRAPS-associated 
TNFR1 mutations could be reversed with anti-oxidant treatment [23]. Increased reactive oxygen species 
(ROS) was observed in TRAPS patient cells and cells transfected with TRAPS-associated TNFR1 at 
baseline and after stimulation with LPS [25]. Specific inhibition of mitochondrial ROS (mtROS), but not 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX), reduced pro-inflammatory 
cytokine production. Increased MAPK activity, possibly through inactivation of MAPK phosphatases 
through oxidation of their catalytic cysteine residues, contributed to enhanced transcription of 
inflammatory genes [25]. Enhanced activation of NF-țB has also been observed in TRAPS patient cells 
[26]. Upon activation, NF-țB translates to the nucleus, where it upregulates target gene expression, 
including genes involved in the production of the pro-inflammatory cytokines, interleukin (IL)-1E, IL-6 
and TNF. The importance of IL-1E in TRAPS pathogenesis is reflected in the strong clinical response of 
TRAPS patients to IL-1E antagonists [27]. The increased IL-6 production in response to LPS in TRAPS 
cells [23, 25] also raises the possibility that IL-6 antagonists may also have therapeutic benefit in 
TRAPS.  
 
Defective autophagy has also been reported in TRAPS monocytes. In one study autophagy but 
not proteasome inhibition increased intracellular mutant and wild type TNFR1 intracellular aggregation 
[28]. Moreover, rescue of TNFR1 membrane localization using geldanamycin restored normal ultra-
structural appearance in TRAPS monocytes and membrane localization of TNFR1 [28]. This rescue was 
reversed by the autophagy inhibitor 3-methyladenine (3-MA), suggesting that autophagy defects could 
be responsible for the failure to clear intracellular mutant TNFR1 aggregates in TRAPS monocytes [28]. 
Autophagy is also important for the degradation of p62, a protein involved in various processes 
including ubiquitination, and intracellular aggregate formation [29, 30]. p62 is degraded by autophagy 
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and increased levels of p62 protein but not mRNA are reported in certain TRAPS mutations, suggesting 
defective clearance of p62 by autophagy rather than increased expression of p62 genes [28]. p62 is 
involved in both caspase 8 activation and apoptosis and also in receptor-interacting protein (RIP) 
activation, resulting in RIP-dependent I kappa B kinase  (IKK), I kappa beta (INB) and ultimately NF-
NB activation [29]. However p62 also increases ubiquitination and Nod-like receptor protein 3 (NLRP3) 
inflammasome degradation, which would be expected to have anti-inflammatory effects and promote the 
clearance of intracellular TNFR1 aggregates. One hypothesis to explain this paradox is that p62-
mediated activation of RIP mitigates these beneficial effects [29]; however, this remains to be validated 
experimentally and, altogether, any potential role for autophagy in TRAPS, either independent or via its 
effects on p62, remains to be clearly defined. Nonetheless, current observations point towards a complex 
model for TRAPS pathogenesis whereby autophagy, the UPR and ROS mediated inflammatory 
pathways operate synergistically to enhance pro-inflammatory cytokine production. 
 
       In addition, protein misfolding may play a role in other autoinflammatory diseases which do 
not involve NLRP3 misfolding (table 1). Mevalonate kinase deficiency (MKD) is a monogenic disease 
with both autoinflammatory and autoimmune features. MKD patients exhibit periodic fever syndrome 
and hypersecretion of IL-1E and IgD. Interestingly, improved efficiency of mevalonate kinase folding in 
MKD does not attenuate clinical symptoms, suggesting that protein misfolding/ stablility may be altered, 
potentially priming the NLRP3 inflammasome by inducing expression of pro-IL-ȕ[31].  The ER stress 
in MKD has been linked to defective mitophagy and neutralization of mtROS in MKD reduces 
inflammasome activity. 
 
Protein misfolding may also play a role in other autoinflammatory diseases which do not directly 
LQYROYH1/5¶s (table 1). Mevalonate kinase deficiency (MKD) is a monogenic disease associated with a 
defect in isoprenoid synthesis with both autoinflammatory and autoimmune features. MKD patients 
exhibit periodic fevers and hyper IgD, and PBMC hypersecrete IL-1E. The ER stress in MKD has been 
linked to defective mitophagy, and neutralization of mtROS in MKD reduces inflammasome activity. 
Interestingly, MKD cells were resistant to reduction in IL-1E production by the autophagy activator 
rapamycin, suggesting that the isoprenoid MKD defect may activate the inflammasome through a 
mechanisms not regulated by autophagy [31].   Genetic defects in the proteasome itself have been 
recently found to cause autoinflammatory disease. Loss of function mutations in PSMB8, which encodes 
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the E5i immunoproteasome subunit, have been associated with a clinical syndrome characterized by 
systemic inflammation, neutophilic lipodystrophy, and in older patients, cardiac and hematologic 
abnormalities [32-34]. Although the immunoproteasome plays a role in processing peptides for antigen 
presentation to T cells, most of the abnormalities found in this syndrome are in innate immunity.  
Interestingly, rather than IL-1E, type I interferon-induced gene expression and target proteins are highly 
induced in this syndrome, perhaps because of accumulation of unfolded protein fragments normally 
degraded by the proteasome induce an interferon response [35, 36] 
 
 
 
A role for autophagy in regulating IL-1E secretion and IL-1E-related autoinflammatory diseases 
 
The secretion of pro-inflammatory cytokine, IL-1Erequires transcriptional activation of the IL-
1E gene and components of the NLRP3 inflammasome: a complex of the NLRP3 protein, also known as 
cryopyrin, caspase-1, apoptosis associated speck-like protein containing a CARD (ASC) and 
CARDINAL, a CARD containing protein. Caspase-1 cleaves IL-1Einto its active form. Innate immune 
stimuli acting through extracellular TLRs and the intracellular Nod-like receptors (NLRs) are major 
activators of transcription of NLRP3 inflammasome components. Diverse particulate stimuli including 
crystalline forms of uric acid, cholesterol, and ATP acting through membrane receptors and dATP acting 
directly on the NLRP3 protein are critical for formation of an active inflammasome and allowing IL-
1Erelease fromthe cell, an event which is also linked to cell death [37, 38]. Activated inflammasomes 
DUHYLVLEOHDVPLFURVFRSLFµVSHFNV¶ZLWKLQ WKHF\WRVRODQGVWUXFWXUDOVWXGLHVKDYHVKRZQWKDW WKH\FDQ
polymerize into large oligomers with potentially thousands of subunits [39]. Gain-of-function mutations 
in the NLRP3 gene are cause de novo and inherited autoinflammatory diseases collectively known as 
cryopyrin-associated periodic syndromes (CAPS) [40]. Pathogenic mutations, predominantly found in 
exon 3, affect the NBD within NLRP3 leading to spontaneous oligomerization and a reduced 
requirement for the second stimulus, ATP, for IL-1Esecretion after activation by innate immune stimuli 
[41]. NLRP3 mutations lead to a spectrum of diseases ranging from the relatively mild familial cold 
autoinflammatory syndrome (FCAS), through Muckle-Wells syndrome (MWS), which includes 
cochlear inflammation leading to hearing loss, to the neonatal-onset multisystem inflammatory disease 
(NOMID), in which there is multi-organ inflammation including sterile meningitis which can lead to 
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neurological impairment and can be fatal without treatment [42-46]. It has recently become apparent that 
autophagy plays a physiological role in disposing of the components of the activated NLRP3 
inflammasome through targeting of ubiquitinated components to the inflammasome and recruitment of 
the autophagy adapter p62 [47-49]. These studies reveal a physiological function for autophagy in 
controlling inflammation. Although CAPS patients can be successfully treated with IL-1 receptor (IL-
1R) antagonists [50, 51], whether activation of autophagy would be another avenue for treatment 
remains an open question.  
 
Recently, activating mutations in the gene coding for another NLR, NLRC4, have been 
associated with an autoinflammatory disease that differs from CAPS [52, 53]. Patients with these 
NLRC4 mutations exhibited early-onset spontaneous fevers, gastrointestinal (GI) inflammation, 
urticaria, splenomegaly and malaise. These symptoms are consistent with macrophage activation 
syndrome (MAS), a severe systemic inflammatory disease involving decreased erythrocytes, leukocytes 
and platelets, abnormal natural killer (NK) cell function, elevated levels of triglycerides and ferritin and 
recurrent fevers. Overexpression of the NLRC4 mutants resulted in constitutive activation of the 
inflammasome and caspase-1 leading to elevated levels of IL-1E and IL-18.  In contrast to CAPS but 
like MAS, monocytes and macrophages with the NLRC4 mutations showed hypersecretion of IL-18 
[52]. Romberg et al. showed that NLRC4 mutant macrophages also exhibited increased apoptosis [53]. 
Treatment with IL-1 blocking agents resulted in partial amelioration of symptoms [52]. Given the role of 
autophagy in regulating IL-1E secretion, it could be a potential additional therapeutic target in treating 
the autoinflammation in patients with disease due to NLRC4 mutations.   
 
 
Protein misfolding and proteotoxic stress in non-Mendelian inflammatory diseases 
 
            Increasing evidence suggests that in polygenic inflammatory diseases, autoinflammation may be 
triggered by misfolded proteins, defects in the UPR or protein degradation pathways. Ankylosing 
spondylitis (AS) is a prototypic spondyloarthropathy involving immune dysregulation, chronic 
inflammation and a strong genetic predisposition. Many genes confer susceptibility to AS, but the HLA-
B27 class I allele has by far the strongest association, with over 90% of AS patients carrying this allele. 
Rather than functioning in its classical role to present specific peptides to CD8+ T cells, evidence has 
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been accumulating to implicate misfolding of HLA-B27 heavy chain as a pathogenic factor in AS. HLA-
B27 molecules tend to misfold [54, 55], and after induction of class I expression with cytokines such as 
interferons, HLA-B27 can induce ER stress and activate the UPR leading to production of IL-6, TNF, 
IL-23, IFN-E and possibly IL-1D [56, 57]In AS patients, ileal biopsies revealed abundant 
misfolded/unfolded MHC class 1 heavy chains colocalizing with the E3 ubiquitin ligase, synoviolin/ 
HRD1 [58]. Studies using rodent models of AS activation of UPR in macrophages led to increased 
levels of IL-23 and upregulation of Th-17 in CD4+ T cells within inflamed tissue [59].  Other studies 
have implicated autophagy defects in the hypersecretion of IL-23 in the gut but not in synovium or 
PBMCs from HLA-B27+ patients with AS [58, 60]. Systemic overexpression of IL-23 in mice leads to 
IL-17 production by innate-like T cells present in the enthesis, the bone-tendon interface where much of 
the inflammation begins in AS, leading to a striking phenocopy of many of the clinical features of AS 
[61]. Taken together, these data implicate HLA-B27 misfolding with the induction of the UPR as a 
pathogenic factor in AS upstream of inflammatory cytokine production.  
 
Polymorphisms in the autophagy regulatory gene, Atg16L1, have been associated with CrohQ¶V
disease, a subtype of inflammatory bowel disease [62]. ATG16L1 deficient macrophages produce 
excessive amounts of cytokines after stimulation with LPS [63], partial deficiency of Atg16L1 can lead 
to reduced production of antimicrobial peptides by Paneth cells in the intestine, impairing antimicrobial 
immunity which may predispose to intestinal inflammation [64]. The ER-stress signal transducing 
protein, XBP-1 is critical in regulating the survival of Paneth cells. In the DSS-induced colitis model, 
conditional deletion of Xbp1 in the intestinal epithelium resulted in Paneth cell disappearance and 
increased susceptibility to colitis due to impaired production of antimicrobial peptides [65]. These 
genetic and functional data build a strong case that in the intestine, autophagy and the UPR are 
important for the survival and function of Paneth cells, and when these processes are defective, 
inflammatory bowel disease can ensue due to defects in control of commensal intestinal flora. 
 
Gout is a crystal arthropathy characterized by the deposition of monosodium urate (MSU) 
crystals in joints and tissues, leading to inflammation and significant morbidity. Uric acid released by 
dying cells interacts with extracellular sodium to form MSU, which acts as a danger signal. The 
phagocytosis of cell debris combined with the MSU signal induce maturation and activation of dendritic 
cells [66], possibly also caused by MSU interactions with CD14, an adaptor molecule for TLR2 and 
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TLR4 [67]. MSU and calcium pyrophosphate dehydrate (CPPD) crystals can induce activation of the 
NLRP3 inflammasome resulting in production of IL-1E [68-70]. In addition to activating the NLRP3 
inflammasome, MSU crystals can also activate autophagosome formation and impair proteasome 
function resulting in p62 accumulation. Inhibition of autophagy through siRNA against ATG16L1 was 
shown to increase caspase-1 activation and IL-1E production [71].  Peripheral neutrophils from healthy 
patients treated with MSU crystals or synovial fluid from patients with active gout lead to neutrophil 
extracellular trap (NET) formation. MSU induced NET formation was dependent on IL-1E and 
phagolysosomal fusion. [72, 73]. Combined with the previously discussed findings that autophagy helps 
to terminate activation of the NLRP3 inflammasome, these results suggest that autophagy may help to 
control inflammation in environmentally triggered IL-1E-related autoinflammatory diseases, such as 
gout.  
 
Rheumatoid arthritis (RA) is a polygenic autoimmune disease with a significant inflammatory 
component. There have been a number of interesting connections identified in RA between aberrant 
UPR and increased inflammatory responses. As in TRAPS, synovial macrophages, synovial fibroblasts 
and PBMCs from RA patients were found to have increased Xbp-1 splicing but not increased expression 
of classical UPR response genes, leading to increased production of pro-inflammatory cytokines, IL-6 
and TNF [74, 75]. Endogenous TLR ligands which have been found in the joint, such as SNAPIN, may 
act to induce this aberrant Xbp-1 splicing and sustain inflammatory responses [76].  
 
Proteotoxic  stress in the pathogenesis of diseases not formerly considered inflammatory 
 
The proteotoxic effects of amyloid-like deposits are a hallmark of many diseases, including type 
II diabetes (T2D) and neurodegenerative diseases such as 3DUNLQVRQ¶VGLVHDVH$O]KHLPHU¶VGLVHDVHDQG
age-related retinal degeneration. Interesting links have been made between insulin insensitivity, obesity, 
ER stress and chronic inflammation in the pathogenesis of T2D [77-80]. T2D is a multifactorial disease 
characterized by insensitivity of target organs such as skeletal muscle, liver and adipose tissue, to the 
effects of insulin. Obesity develops because insulin resistance leads to increased lipolysis and abnormal 
fat deposits, decreased glucose uptake in skeletal muscle and enhanced gluconeogenesis in the liver. 
Adipose tissue, which consists of preadipocytes, adipocytes, and vascular cells, has important endocrine 
functions including the secretion of adipokines (TNF, IL-6, leptin, adiponectin and more) and monocyte 
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chemoattractant protein 1 (MCP-1) [80, 81]. During inflammation, infiltrating macrophages are found in 
adipose tissue. Studies show that markers of ER stress and UPR are elevated in tissues from diabetic 
and/or obese humans and rodents [78, 82-84]. The enormous adipocyte size, accumulation of lipids and 
increased cellularity of adipose tissue in obesity are thought to contribute to local tissue hypoxia [85]. 
Hypoxia induces ER stress and PERK-dependent eIF2D phosphorylation leading to protein synthesis 
inhibition [86]. In hypertrophic adipocytes, ER stress upregulates UPR proteins, including both CHOP 
and GRP78, the inflammatory and apoptotic pathways [78, 87]. Analysis of Xbp1+/- mice on a high fat 
diet revealed persistent hyperinsulinemia, hyperglycemia, elevated C-peptide and suppression of insulin 
signaling in adipocytes [78].  Thus, ER stress may reinforce insulin resistance and may lead to pro-
inflammatory cytokine secretion by adipocytes. TNF and IL-6 have been shown to activate ER stress in 
adipocytes and subclinical inflammation has been observed T2DM and insulin  states [88]. Obese mice 
lacking either TNF or its receptors, TNFR1 and TNFR2, showed decreased insulin resistance and low 
blood levels of free fatty acids [88]. In a study of patients with obesity-induced insulin resistance, 
adipose tissue expression of TNF and IL-6 mRNA was significantly elevated and in vitro stimulation of 
human adipocytes with TNF caused increased PPARE/G mRNA production but decreased its target 
genes and DNA-binding activity in a NF-NB dependent manner [89].  In skeletal muscle cells, PPARE/G 
agonism inhibited palmitate-induced ER stress and significantly decreased levels of pro-inflammatory 
cytokines, TNF and IL-6, in an AMPK dependent manner [90]. The inflammatory environment in 
T2DM could be abrogated by increased activity of PPARE/G target genes such as SIRT1 [91, 92]. 
 
Emerging evidence suggests that IL-1E may also play an important role in T2D pathogenesis. 
Pancreatic Ecells secrete insulin and islet amyloid polypeptide (IAPP), a major component of 
extracellular amyloid E aggregates are frequently found in the pancreas of diabetic patients. In primed 
dendritic cells, IAPP oligomers can activate the NLRP3 inflammasome leading to production of IL-1E 
[93]. IL-1E secretion was significantly decreased with exposure to inhibitors of caspase-1, glucose 
metabolism and lysosomal acidification. Glyburide, a sulfonylurea used in T2DM treatment, also 
inhibited IL-1E production [93]. Soluble IAPP oligomers, and not the higher order fibrils, appear to be 
critical for IL-1Eproduction. One rodent model of islet amyloid deposition is the transgenic mouse 
expressing human IAPP (IAPP-TG) on a high fat diet for 1 year [94]. Pancreatic islets from IAPP-TG 
mice showed regions of decreased insulin, abundant amyloid E deposits and increased intracellular IL-
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1E. The amyloid E protein co-localized with IL-1E within IAPP-TG islets. However, there was no 
significant difference in the proportion of macrophages in islets from IAPP-TG mice versus wild-type 
controls. A functional analysis of phagocytes isolated from pancreatic islets in IAPP-TG mice could 
provide definitive proof of which cells (beta cells, macrophages or dendritic cells) produce IL-1E. 
Studies using IL-1 antagonists have been shown to ameliorate insulin resistance and obesity [95, 96] and 
this collectively suggests an autoinflammatory component in T2DM. 
 
Proteotoxic stress and inflammation have been found to play an increasingly essential role in the 
initiation and/or progression of neurodegenerative diseases. 3DUNLQVRQ¶VGLVHDVH3'LVFKDUDFWHUL]Hd by 
chronic inflammation, neurotoxicity, progressive loss of dopaminergic neurons culminating in a 
movement disorder and progressive dementia. PD pathogenesis involves genetic abnormalities, protein 
misfolding, defective mitophagy and neuroinflammation. Loci multiplication and mutations in the D-
synuclein gene, SNCA, predispose to autosomal dominant PD [97-99]. However, most patients have 
sporadic forms of PD in which aging and inefficient proteasome degradation results in accumulation of 
D-synuclein and inflammation [100-104]. Misfolded D-synuclein accumulates into cytoplasmic protein 
aggregates called Lewy bodies in presynaptic neurons [105, 106]. Additional components of Lewy 
bodies include ubiquitin, the E3 ubiquitin ligase, Parkin and the D-synuclein interacting protein, 
synphilin-1. Synphilin-1 can be ubiquitinated by Parkin leading to its degradation [107].  
 
In a rat model of PD, overexpression of human D-synuclein in the substantia nigra leads to ER 
stress and upregulation of the UPR response. The study showed a trend towards increased splicing of 
XBP1, with significantly increased levels of ATF4, pATF6 and CHOP, indicating activation of the 
PERK and ATF6 pathways and their culmination in apoptosis [108]. Overexpressed human D-synuclein 
was found to associate with GRP78/BiP leading to its effective removal and prevention of neuronal 
apoptosis [108]. In addition to the proteasome and UPR, autophagy has been implicated in the 
degradation of D-synuclein and PD pathogenesis [109, 110]. Aging neurons exhibit increasingly 
impaired chaperone mediated autophagy (CMA). Interestingly CMA has been shown to degrade D-
synuclein [103]. However, the mutant, oligomeric or dopamine-treated D-synuclein prevent its CMA-
mediated degradation by blocking uptake into lysosomes [111, 112]. Winslow et al. showed that D-
synuclein overexpression inhibited autophagosome formation in autophagy [113]. Defective 
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mitochondria accumulate in aging neurons leading to neuronal toxicity and loss. Mitophagy is another 
form of autophagy that selectively degrades these defective mitochondria. Parkin reduces ER-stress 
mediated mitochondrial damage by preventing excessive fragmentation and induction of autophagy 
[114]. Caspase-1 cleavage and Parkin activation could generate a positive feedback loop whereby 
increased ER stress leads to increased caspase-1 mediated cleavage of Parkin. Thus, the protective 
effects of Parkin are suppressed [115]. Neuroinflammation observed in PD is attributed to activated 
microglia, which are abundant in the post-mortem brains of PD patients [116, 117]. Postmortem CSF 
and brain tissue from PD patients have elevated TNF and IFN-J levels [118, 119]. Rodent models of 
chronic LPS infusion lead to brain inflammation with subsequent delay and selective degeneration of 
dopaminergic neurons [120]. Peripheral LPS administration resulted in TNF production, which crosses 
the blood brain barrier via TNF receptors, leading to neuroinflammation [121, 122]. The microglia in PD 
express pro-inflammatory cytokines, such as IL-1E, TNF, nitric oxide (NO) and ROS [120, 123-125]. 
These studies suggest that the establishment and maintenance of an inflammatory microenvironment and 
failure of protein degradation pathways may together, speed the destruction of dopaminergic neurons in 
PD. 
 
$O]KHLPHU¶V GLVHDVH $' LV FKDUDFWHUL]HG E\ WKH SURJUHVVLYH DFFXPXODWLRQ RI extracellular 
amyloid E plaques, intracellular neurofibrillary tau, neuroinflammation, extensive neuronal cell death 
and dementia [126]. Increased expression of GRP78 was found in brain tissue of AD patients at the early 
pathological stage of AD compared to controls without dementia [127]. In addition, neurons from AD 
patients have increased phosphorylated PERK, IRE1D and eILF2D [128, 129]. The activated UPR was 
enhanced in neurons with a diffuse pattern of phosphorylated tau [128], thus, suggesting that the UPR 
activation requires tau but precedes formation of neurofibrillary tau tangles. Microglia and infiltrating 
mononuclear phagocytes are recruited to amyloid E plaques, become activated and phagocytose amyloid 
E leading to activation of the NLRP3 inflammasome and production of pro-inflammatory cytokines, 
specifically IL-1E [130-134]. AD patients and rodent models showed increased IL-1E expression in 
microglia isolated from amyloid E plaques and increased CSF levels of IL-1E [135]. Studies show that 
like PD, autophagy may prevent the accumulation of amyloid E plaques in AD. Brain tissue from AD 
patients shows decreased levels of Beclin-1 and mice deficient in Beclin-1 exhibited amyloid 
Eaccumulation and neurodegeneration [136]. Lentiviral expression of Beclin-1 in these mice 
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significantly decreased the amyloidE meditated pathology [136]. Thus, inefficient UPR combined with 
dysfunctional autophagy lead to failed clearance of misfolded protein aggregates, subsequent activation 
of microglia and significant neuroinflammation in AD.   
 
Age-related macular degeneration (AMD) is characterized by progressive destruction of retinal 
photoreceptors in the macula and retinal pigment epithelium (RPE) resulting in blindness [137, 138]. 
AMD is associated with multiple risk factors including age, race, genetic susceptibility, smoking, 
obesity and high blood pressure [137, 139-141]. Proposed mechanisms of AMD pathogenesis include 
chronic oxidative stress, ER stress, light damage, increased polyunsaturated fatty acids, abnormal 
phagocytosis, complement activation and inflammation [142-152]. In human RPE, induction of 
oxidative stress by H2O2 or photo-oxidation led to proteasome inhibition and accumulation of 
polyubiquitinated proteins and aggregates [152]. Under conditions of proteasome inhibition, the 
chaperone mediated autophagy (CMA)-lysosome pathway plays an important role in the removal of 
accumulated proteins [153]. Interestingly, inhibition of both the proteasome and CMA resulted in 
increased cell death. Thus, retinal cells require protective measures to ensure cell survival. In a murine 
model of light-induced retinal degeneration, Xbp1 deficiency caused a decrease in anti-oxidant genes, 
superoxide dismutase (SOD) 1, SOD2 and glutathione synthase. In addition, increased oxidative stress 
and susceptibility to oxidative damage were observed. This study showed that XBP-1 has an antioxidant 
function that may facilitate cell survival and prevent retinal degeneration in AMD [154].   
 
The early stage of macular degeneration in AMD is characterized by local inflammation leading 
to deposition of drusen, an extracellular debris-like material that accumulates beneath RPE cells and 
%UXFK¶VPHPEUDQH[155]. Studies show that drusen contains oxidized proteins, complement and amyloid 
E. Oxidative stress causes modifications in drusen proteins that may facilitate the formation of drusen.  
Complement pathway dysregulation is thought to play a critical role in the formation of drusen [142, 
144, 148]. An analysis of drusen components showed an abundance of regulatory proteins of the 
common complement pathway.  In addition, RPE cells overlying drusen had increased cytoplasmic 
levels of complement inhibitors. Similar to T2DM and $O]KHLPHU¶VGLVHDVHGUXVHQFRQVLVWVRIDP\ORLG
beta, a pro-inflammatory molecule that also activates complement [142] and the NLRP3 inflammasome 
[130, 132]. Drusen components, complement C1q and oxidized lipids, activate the NLRP3 
inflammasome resulting in increased production of the pro-inflammatory cytokines, IL-1E and IL-18 
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[156].  IL-18 is thought to protect against AMD by inhibiting VEGF and thus preventing the 
pathological neovascularization in wet AMD. These studies show that drusen biogenesis and 
maintenance is dependent on an inflammatory milieu with autoinflammatory features. 
 
The interplay of the UPR and various metabolic pathways has raised the possibility that targeted 
intervention at key points in specific metabolic pathways could be effective in a range of 
autoinflammatory pathologies. XBP1s is a direct transcriptional activator of the hexosamine biosynthetic 
(HBP) pathway, via Xbp1s-dependent transcription of genes coding for key, rate-limiting enzymes 
[157]. This UPR-HBP axis is triggered in a variety of stress conditions, including ischemia-reperfusion 
(I/R) injury, where acute stimulation of Xbp1s confers robust cardio-protection in part via induction of 
HBP. A separate study of I/R injury showed that ischemic accumulation of succinate controls 
reperfusion injury through mtROS [158]. Therefore, limiting succinate accumulation has marked 
potential for management of a range of conditions, including autoinflammatory diseases resistant to 
standard therapies, as well as more widespread conditions, where dysregulation of the UPR underlies 
pathogenesis. Blockade of XBP1 splicing by inhibition RI,5(Įhas shown promise in the treatment of 
myeloma [159]. Collectively, these studies reveal that the effects of Xbp1s are very context dependent 
and that the UPR may play a key role to protect cells under stress in addition to the more publicized 
contribution to causing disease.  
 
 
Conclusions and implications for future therapies 
 
The diverse diseases arising from protein misfolding, defective clearance and autoinflammation 
form a continuum in which cumulative cellular stress results in significant pathology and, in some cases, 
severe disease and death. In TRAPS and MKD deficiency, accumulation of mutant proteins leads to ER 
stress, UPR activation, abnormal signaling and autoinflammation. In CAS and MAS, NLRP3 and 
NLRC4 mutants undergo improper oligomerization, with constitutive activation of the inflammasome 
that results in IL-1 and IL-18 hypersecretion. In spondyloarthropathies, abnormal UPR activation leads 
to overproduction of pro-inflammatory cytokines. Interestingly, the UPR and autophagy have dual roles 
in both promoting and controlling inflammation. Autophagy gene polymorphisms and XBP-1 deficiency 
lead to impaired integrity of Paneth cells, resulting in IBD. Furthermore, the protective functions of 
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XBP-1 are demonstrated in ischemia-reperfusion injury and multiple myeloma. In T2D and AMD, 
accumulating extracellular amyloid deposits may be phagocytosed by macrophages/microglia leading to 
inflammasome activation and increased IL-1E production. Intracellular aggregates of proteins such as D-
synuclein accumulate in PD and AD due to marked impairment of protein disposal mechanisms.   
 
The advances in our understanding of the pathogenesis of autoinflammatory diseases and 
recognition that other diseases have an autoinflammatory component related to altered protein 
homeostasis have underlined the pressing need for development of novel therapies for these conditions 
and raised the possibility that these therapies may also treat a wider spectrum of diseases.  The goals of 
such therapies include effective prevention of protein accumulation, enhancement of clearance 
mechanisms, suppression of ROS and inflammation. Protein misfolding within the ER leads to 
activation of the UPR, thus therapies focused on augmenting the UPR could be highly beneficial. 
However, given the potential for an activated UPR to lead to inflammation and increased disease 
severity, tight regulation is essential to the success of any pharmacological strategy. In diseases with 
aberrant ROS production and oxidative stress like AMD and TRAPS, useful therapies may include anti-
oxidants include anti-oxidants as adjunct therapies [158]. Patients with autoinflammatory diseases, who 
are treated with cytokine blockade, show significant attenuation in symptoms and disease progression. 
IL-1 blockade is effective in treating CAPS, gout and T2D. TNF blockade therapy resulted in limited 
success in TRAPS patients. Since proteasome degradation and autophagy are anti-inflammatory possible 
interventions may involve enhancing these pathways to effectively reduce NLRP3 activation and 
inflammation. Small molecules that can directly block the NLRP3 inflammasome and related signalling 
pathways have recently shown promise in pre-clinical studies [160, 161]. Clinical trials of agents 
designed to modulate proteotoxic stress and the inflammasome, in combination with traditional 
therapies, will determine the therapeutic impact of these new insights into the connections between 
protein homeostasis and autoinflammation.   
 
Acknowledgements 
 
The authors would like to thank the Leeds Teaching Hospitals Special Trustees (9/R01/2002), Arthritis 
Research UK (grant 19269) and the NIHR-Leeds Musculoskeletal Biomedical Research Unit who 
funded McD, and the Wolfson Foundation who funded an intercalated degree research scholarship for 
  18 
SH. RMS and AA are supported by the NIAMS intramural research program, and AA is an NIH UGSP 
scholar. 
  
  19 
 
REFERENCES 
 
 
1. Hetz, C., et al., The unfolded protein response: integrating stress signals through the stress sensor IRE1alpha. 
Physiol Rev, 2011. 91(4): p. 1219-43. 
2. Wu, J. and R.J. Kaufman, From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death 
Differ, 2006. 13(3): p. 374-84. 
3. Urano, F., et al., Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase 
IRE1. Science, 2000. 287(5453): p. 664-6. 
4. Virgin, H.W. and B. Levine, Autophagy genes in immunity. Nat Immunol, 2009. 10(5): p. 461-70. 
5. Levine, B. and G. Kroemer, Autophagy in the pathogenesis of disease. Cell, 2008. 132(1): p. 27-42. 
6. Park, H., et al., Lighting the fires within: the cell biology of autoinflammatory diseases. Nat. Rev. Immunol., 2012. 
12(8): p. 570-580. 
7. McDermott, M.F., et al., Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, 
define a family of dominantly inherited autoinflammatory syndromes. Cell, 1999. 97(1): p. 133-144. 
8. McGonagle, D.G. and M.F. McDermott, A proposed classification of the immunological diseases. PLoS Medicine, 
2006. 3(8): p. e297. 
9. Savic, S., et al., Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new 
treatment perspectives. Best Practise and Research Clinical Rheumatology, 2012. 26(4): p. 505-533. 
10. Yao, Q. and D.E. Furst, Autoinflammatory diseases: an update of clinical and genetic aspects. Rheumatology 
(Oxford), 2008. 47(7): p. 946-951. 
11. McKusick, A.V. Periodic fever, familial, autosomal dominant (OMIM:142680) [Online] . 1986 2008 [cited 2015 
Feb 07]. 
12. Askentijevich, I. TNFRSF1A sequence variants [Online] . 2014  [cited 2015 Feb 07]; Available from: 
http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php?n=2. 
13. Cantarini, L., et al., Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): State of the art and 
future perspectives. Autoimmunity reviews, 2012. 12(1): p. 38-43. 
14. Simon, A., et al., Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 
1-associated periodic fever syndrome. Proceedings of the National Academy of Sciences of the United States of 
America, 2010. 107(21): p. 9801-9806. 
15. Xanthoulea, S., et al., Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune 
activation that balance opposing TNF functions in infectious and inflammatory diseases. Journal of Experimental 
Medicine, 2004. 200(3): p. 367-376. 
16. Huggins, M.L., et al., Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor 
necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis and Rheumatism, 
2004. 50(8): p. 2651-2659. 
17. Todd, I., et al., Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated 
periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis and Rheumatism, 
2007. 56(8): p. 2765-2773. 
18. Todd, I., et al., Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic 
syndrome retain signalling functions but show abnormal behaviour. Immunology, 2004. 113(1): p. 65-79. 
19. Rebelo, S.L., et al., Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor 
necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. 
Arthritis and Rheumatism, 2006. 54(8): p. 2674-2687. 
20. Lobito, A.A., et al., Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by 
TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood, 2006. 108(4): p. 1320-1327. 
21. Yousaf, N., et al., Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated 
periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-
kappaB activation. Arthritis and Rheumatism, 2005. 52(9): p. 2906-2916. 
22. Nedjai, B., et al., Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in 
tumor necrosis factor receptor-associated periodic syndrome. Arthritis and Rheumatism, 2008. 58(1): p. 273-283. 
  20 
23. Dickie, L.J., et al., Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis 
of tumour necrosis factor receptor-associated periodic syndrome. Annals of Rheumatic Diseases, 2012. 71(12): p. 
2035-2043. 
24. Martinon, F., et al., TLR activation of the transcription factor XBP1 regulates innate immune responses in 
macrophages. Nature Immunology, 2010. 11(5): p. 411-418. 
25. Bulua, A.C., et al., Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are 
elevated in TNFR1-associated periodic syndrome (TRAPS). Journal of Experimental Medicine, 2011. 208(3): p. 
519-533. 
26. Churchman, S.M., et al., A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF-
kappaB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic 
syndrome (TRAPS). Ann Rheum Dis, 2008. 67(11): p. 1589-95. 
27. Gattorno, M., et al., Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated 
periodic syndrome. Arthritis and Rheumatism, 2008. 58(5): p. 1516-1520. 
28. Bachetti, T., et al., Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome 
(TRAPS). Annals of the Rheumatic Diseases, 2013. 72(6): p. 1044-1052. 
29. Bachetti, T. and I. Ceccherini, Tumor necrosis factor receptor-associated periodic syndrome as a model linking 
autophagy and inflammation in protein aggregation disease. Journal of Molecular Medicine 2014. 92(6): p. 582-
594. 
30. Moscat, J. and M.T. Diaz-Meco, p62 at the crossroads of autophagy, apoptosis, and cancer. Cell, 2009. 137(6): p. 
1001-1004. 
31. van der Burgh, R., et al., Defects in mitochondrial clearance predispose human monocytes to interleukin-1beta 
hypersecretion. J Biol Chem, 2014. 289(8): p. 5000-12. 
32. Agarwal, A.K., et al., PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle 
atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. American journal of human genetics, 
2010. 87(6): p. 866-72. 
33. Arima, K., et al., Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the 
autoinflammatory disorder, Nakajo-Nishimura syndrome. Proceedings of the National Academy of Sciences, 2011. 
108(21852578): p. 14914-9. 
34. Kitamura, A., et al., A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and 
lipodystrophy in humans. Journal of Clinical Investigation, 2011. 121(10): p. 4150-4160. 
35. Liu, Y., et al., Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with 
lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum, 
2012. 64(3): p. 895-907. 
36. Seifert, U., et al., Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell, 
2010. 142(4): p. 613-24. 
37. Strowig, T., et al., Inflammasomes in health and disease. Nature, 2012. 481(7381): p. 278-86. 
38. Duncan, J.A., et al., Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate 
inflammatory signaling. Proc Natl Acad Sci U S A, 2007. 104(19): p. 8041-6. 
39. Lu, M., et al., Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like 
receptor protein 3 inflammasome activation. Neurobiol Aging, 2014. 35(2): p. 421-30. 
40. Chae, J.J., et al., Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation 
and severe autoinflammation in mice. Immunity, 2011. 34(5): p. 755-68. 
41. Aksentijevich, I., et al., The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American 
patients and a new cryopyrin model. Arthritis Rheum, 2007. 56(4): p. 1273-85. 
42. Hoffman, H.M., A.A. Wanderer, and D.H. Broide, Familial cold autoinflammatory syndrome: phenotype and 
genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol, 2001. 108(4): p. 615-20. 
43. Dode, C., et al., New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold 
urticaria: a novel mutation underlies both syndromes. Am J Hum Genet, 2002. 70(6): p. 1498-506. 
44. Agostini, L., et al., NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells 
autoinflammatory disorder. Immunity, 2004. 20(3): p. 319-25. 
45. Aksentijevich, I., et al., De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in 
patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of 
pyrin-associated autoinflammatory diseases. Arthritis Rheum, 2002. 46(12): p. 3340-8. 
46. Feldmann, J., et al., Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in 
CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet, 2002. 71(1): p. 
198-203. 
  21 
47. Harris, J., et al., Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem, 
2011. 286(11): p. 9587-97. 
48. Nakahira, K., et al., Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial 
DNA mediated by the NALP3 inflammasome. Nat Immunol, 2011. 12(3): p. 222-30. 
49. Shi, C.S., et al., Activation of autophagy by inflammatory signals limits IL-1beta production by targeting 
ubiquitinated inflammasomes for destruction. Nat Immunol, 2012. 13(3): p. 255-63. 
50. Goldbach-Mansky, R., et al., Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta 
inhibition. N Engl J Med, 2006. 355(6): p. 581-92. 
51. Hawkins, P.N., H.J. Lachmann, and M.F. McDermott, Interleukin-1-receptor antagonist in the Muckle-Wells 
syndrome. N Engl J Med, 2003. 348(25): p. 2583-4. 
52. Canna, S.W., et al., An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent 
macrophage activation syndrome. Nat Genet, 2014. 46(10): p. 1140-6. 
53. Romberg, N., et al., Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet, 2014. 
46(10): p. 1135-9. 
54. Mear, J.P., et al., Misfolding of HLA-B27 as a Result of Its B Pocket Suggests a Novel Mechanism for Its Role in 
Susceptibility to Spondyloarthropathies. The Journal of Immunology, 1999. 163(12): p. 6665-6670. 
55. Dangoria, N.S., et al., HLA-B27 Misfolding Is Associated with Aberrant Intermolecular Disulfide Bond Formation 
(Dimerization) in the Endoplasmic Reticulum. Journal of Biological Chemistry, 2002. 277(26): p. 23459-23468. 
56. Turner, M.J., et al., HLA±B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the 
magnitude of the unfolded protein response in transgenic rats: Implications for the pathogenesis of spondylarthritis-
like disease. Arthritis & Rheumatism, 2007. 56(1): p. 215-223. 
57. Turner, M.J., et al., HLA-B27 Misfolding in Transgenic Rats Is Associated with Activation of the Unfolded Protein 
Response. The Journal of Immunology, 2005. 175(4): p. 2438-2448. 
58. Ciccia, F., et al., Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 
in the gut of patients with ankylosing spondylitis and subclinical gut inflammation. Annals of the Rheumatic 
Diseases, 2014. 73(8): p. 1566-1574. 
59. DeLay, M.L., et al., HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and 
are associated with Th17 activation in transgenic rats. Arthritis Rheum, 2009. 60(9): p. 2633-43. 
60. Neerinckx, B., S. Carter, and R.J. Lories, No evidence for a critical role of the unfolded protein response in 
synovium and blood of patients with ankylosing spondylitis. Ann Rheum Dis, 2014. 73(3): p. 629-30. 
61. Sherlock, J.P., et al., IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal 
resident T cells. Nat Med, 2012. 18(7): p. 1069-76. 
62. Rioux, J.D., et al., Genome-wide association study identifies new susceptibility loci for Crohn disease and 
implicates autophagy in disease pathogenesis. Nat Genet, 2007. 39(5): p. 596-604. 
63. Saitoh, T., et al., Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1[bgr] production. Nature, 
2008. 456(7219): p. 264-268. 
64. Cadwell, K., et al., A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth 
cells. Nature, 2008. 456(7219): p. 259-63. 
65. Kaser, A., et al., XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory 
bowel disease. Cell, 2008. 134(5): p. 743-756. 
66. Shi, Y., J.E. Evans, and K.L. Rock, Molecular identification of a danger signal that alerts the immune system to 
dying cells. Nature, 2003. 425(6957): p. 516-521. 
67. Scott, P., et al., Engagement of CD14 Mediates the Inflammatory Potential of Monosodium Urate Crystals. The 
Journal of Immunology, 2006. 177(9): p. 6370-6378. 
68. Martinon, F., et al., Gout-associated uric acid crystals activated the NALP3 inflammasome. Nature, 2006. 440(9): p. 
237. 
69. Di Giovine, F.S., et al., Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial 
fibroblast mitogenesis by urate crystal-induced IL 1. The Journal of Immunology, 1987. 138(10): p. 3213-8. 
70. di Giovine, F.S., et al., Urate crystals stimulate production of tumor necrosis factor alpha from human blood 
monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest, 1991. 
87(4): p. 1375-81. 
71. Choe, J.Y., et al., Enhanced p62 expression through impaired proteasomal degradation is involved in caspase-1 
activation in monosodium urate crystal-induced interleukin-1b expression. Rheumatology (Oxford), 2014. 53(6): p. 
1043-53. 
72. Allaeys, I., F. Marceau, and P.E. Poubelle, NLRP3 promotes autophagy of urate crystals phagocytized by human 
osteoblasts. Arthritis Res Ther, 2013. 15(6): p. R176. 
  22 
73. Mitroulis, I., et al., Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related 
signaling in gout. PLoS One, 2011. 6(12): p. e29318. 
74. Savic, S., et al., TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes(). 
Journal of Autoimmunity, 2014. 50(100): p. 59-66. 
75. Qiu, Q., et al., Toll-like receptor-mediated IRE1alpha activation as a therapeutic target for inflammatory arthritis. 
EMBO J, 2013. 32(18): p. 2477-90. 
76. Shi, B., et al., SNAPIN: an endogenous toll-like receptor ligand in rheumatoid arthritis. Annals of the Rheumatic 
Diseases, 2012. 71(8): p. 1411-1417. 
77. Hirosumi, J., et al., A central role for JNK in obesity and insulin resistance. Nature, 2002. 420(6913): p. 333-336. 
78. Ozcan, U., et al., Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes. Science, 2004. 
306(5695): p. 457-461. 
79. Ozcan, U., et al., Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of 
Type 2 Diabetes. Science, 2006. 313(5790): p. 1137-1140. 
80. Samuel, V.T. and G.I. Shulman, Integrating Mechanisms for Insulin Resistance: Common Threads and Missing 
Links. Cell, 2012. 148(5): p. 852-871. 
81. Wang, B., I.S. Wood, and P. Trayhurn, Dysregulation of the expression and secretion of inflammation-related 
adipokines by hypoxia in human adipocytes. PflҀ|gers Archiv - European Journal of Physiology, 2007. 455(3): p. 
479-492. 
82. Boden, G., et al., IncreDVH LQ (QGRSODVPLF 5HWLFXOXP 6WUHVVÃbu5HODWHG 3URWHLQV DQG *HQHV LQ $GLSRVH 7LVVXH RI
Obese, Insulin-Resistant Individuals. Diabetes, 2008. 57(9): p. 2438-2444. 
83. Sharma, N.K., et al., Endoplasmic Reticulum Stress Markers Are Associated with Obesity in Nondiabetic Subjects. 
The Journal of Clinical Endocrinology & Metabolism, 2008. 93(11): p. 4532-4541. 
84. Gregor, M.F., et al., Endoplasmic Reticulum Stress Is Reduced in Tissues of Obese Subjects After Weight Loss. 
Diabetes, 2009. 58(3): p. 693-700. 
85. Brook, C.G., J.K. Lloyd, and O.H. Wolf, Relation between age of onset of obesity and size and number of adipose 
cells. Br Med J, 1972. 2(5804): p. 25-7. 
86. Koumenis, C., et al., Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase 
PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol, 2002. 22(21): p. 7405-16. 
87. Hosogai, N., et al., Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation. Diabetes, 
2007. 56(4): p. 901-911. 
88. Uysal, K.T., et al., Protection from obesity-induced insulin resistance in mice lacking TNF-[alpha] function. Nature, 
1997. 389(6651): p. 610-614. 
89. Serrano-Marco, L., et al., TNF-a inhibits PPAR beta/delta activity and SIRT1 expression through NF-kB in human 
adipocytes. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012. 1821(9): p. 1177-
1185. 
90. Salvado, L., et al., PPARbeta/delta prevents endoplasmic reticulum stress-associated inflammation and insulin 
resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia, 2014. 57(10): p. 2126-
2135. 
91. Yoshizaki, T., et al., SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell 
Biol, 2009. 29(5): p. 1363-74. 
92. Yoshizaki, T., et al., SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J 
Physiol Endocrinol Metab, 2010. 298(3): p. E419-28. 
93. Masters, S.L., et al., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for 
enhanced IL-1beta in type 2 diabetes. Nat Immunol, 2010. 11(10): p. 897-904. 
94. Matveyenko, A.V. and P.C. Butler, Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 
diabetes. ILAR J, 2006. 47(3): p. 225-33. 
95. Ehses, J.A., et al., IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. 
Proc Natl Acad Sci U S A, 2009. 106(33): p. 13998-4003. 
96. Larsen, C.M., et al., Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes 
care, 2009. 32(9): p. 1663-8. 
97. Polymeropoulos, M.H., et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. 
Science, 1997. 276(5321): p. 2045-7. 
98. Chartier-Harlin, M.C., et al., Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 
2004. 364(9440): p. 1167-9. 
99. Singleton, A.B., et al., alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003. 302(5646): p. 
841. 
  23 
100. McNaught, K.S., et al., Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's 
disease. Ann Neurol, 2004. 56(1): p. 149-62. 
101. McNaught, K.S., et al., Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol, 2003. 179(1): p. 
38-46. 
102. Snyder, H., et al., Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit 
proteasomal function. J Biol Chem, 2003. 278(14): p. 11753-9. 
103. Webb, J.L., et al., Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem, 2003. 278(27): 
p. 25009-13. 
104. Pintado, C., et al., Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated 
proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus. J 
Neuroinflammation, 2012. 9(1): p. 87. 
105. Spillantini, M.G., et al., Alpha-synuclein in Lewy bodies. Nature, 1997. 388(6645): p. 839-40. 
106. Spillantini, M.G., et al., alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and 
dementia with lewy bodies. Proc Natl Acad Sci U S A, 1998. 95(11): p. 6469-73. 
107. Chung, K.K., et al., Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for 
Lewy-body formation in Parkinson disease. Nat Med, 2001. 7(10): p. 1144-50. 
108. Gorbatyuk, M.S., et al., Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of 
Parkinson disease. Mol Ther, 2012. 20(7): p. 1327-37. 
109. Komatsu, M., et al., Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature, 
2006. 441(7095): p. 880-4. 
110. Hara, T., et al., Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature, 
2006. 441(7095): p. 885-9. 
111. Martinez-Vicente, M., et al., Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin 
Invest, 2008. 118(2): p. 777-88. 
112. Cuervo, A.M., et al., Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science, 
2004. 305(5688): p. 1292-5. 
113. Winslow, A.R., et al., alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol, 
2010. 190(6): p. 1023-37. 
114. Narendra, D., et al., Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell 
Biol, 2008. 183(5): p. 795-803. 
115. Yu, J., et al., Inflammasome activation leads to Caspase-1-dependent mitochondrial damage and block of 
mitophagy. Proc Natl Acad Sci U S A, 2014. 111(43): p. 15514-9. 
116. McGeer, P.L., et al., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and 
Alzheimer's disease brains. Neurology, 1988. 38(8): p. 1285-91. 
117. Gao, H.M., et al., Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic 
neurodegeneration. J Neurosci, 2008. 28(30): p. 7687-98. 
118. Mogi, M., et al., Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha 
are elevated in the brain from parkinsonian patients. Neurosci Lett, 1994. 180(2): p. 147-50. 
119. Mogi, M., et al., Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid 
from parkinsonian patients. Neurosci Lett, 1994. 165(1-2): p. 208-10. 
120. Gao, H.M., et al., Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic 
neurons: relevance to Parkinson's disease. J Neurochem, 2002. 81(6): p. 1285-97. 
121. Qin, L., et al., Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia, 2007. 
55(5): p. 453-62. 
122. Pan, W. and A.J. Kastin, TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice. 
Exp Neurol, 2002. 174(2): p. 193-200. 
123. Hetier, E., et al., Modulation of interleukin-1 and tumor necrosis factor expression by beta-adrenergic agonists in 
mouse ameboid microglial cells. Exp Brain Res, 1991. 86(2): p. 407-13. 
124. Pott Godoy, M.C., et al., Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model 
of Parkinson's disease. Brain, 2008. 131(Pt 7): p. 1880-94. 
125. Ferrari, C.C., et al., Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-
1beta in the substantia nigra. Neurobiol Dis, 2006. 24(1): p. 183-93. 
126. Meyer-Luehmann, M., et al., Rapid appearance and local toxicity of amyloid-¯ SODTXHV LQ D PRXVH PRGHO RI
$O]KHLPHUÃb{VGLVHDVH Nature, 2008. 451(7179): p. 720-724. 
127. Hoozemans, J.J., et al., The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol, 2005. 
110(2): p. 165-72. 
  24 
128. Hoozemans, J.J., et al., The unfolded protein response is activated in pretangle neurons in Alzheimer's disease 
hippocampus. Am J Pathol, 2009. 174(4): p. 1241-51. 
129. Chang, R.C., et al., Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal 
degeneration in Alzheimer's disease. Neuroreport, 2002. 13(18): p. 2429-32. 
130. Halle, A., et al., The NALP3 inflammasome is involved in the innate immune response to amyloid-[beta]. Nat 
Immunol, 2008. 9(8): p. 857-865. 
131. Ittner, L.M. and J.r. GҀѨtz, Amyloid-¯ DQG WDX Ãbv D WR[LF SDV GH GHX[ LQ $O]KHLPHU
V GLVHDVH Nat Rev 
Neurosci, 2011. 12(2): p. 67-72. 
132. Masters, S.L. and L.A.J. O'Neill, Disease-associated amyloid and misfolded protein aggregates activate the 
inflammasome. Trends in Molecular Medicine, 2011. 17(5): p. 276-282. 
133. Simard, A.R., et al., Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation 
in Alzheimer's Disease. Neuron. 49(4): p. 489-502. 
134. Itagaki, S., et al., Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J 
Neuroimmunol, 1989. 24(3): p. 173-82. 
135. Blum-Degen, D., et al., Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's 
and de novo Parkinson's disease patients. Neurosci Lett, 1995. 202(1-2): p. 17-20. 
136. Pickford, F., et al., The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and 
regulates amyloid beta accumulation in mice. J Clin Invest, 2008. 118(6): p. 2190-9. 
137. Jager, R.D., W.F. Mieler, and J.W. Miller, Age-Related Macular Degeneration. New England Journal of Medicine, 
2008. 358(24): p. 2606-2617. 
138. Gao, H. and J.G. Hollyfield, Aging of the human retina: Differential loss of neurons and retinal pigment epithelial 
cells. Investigative Ophthalmology and Visual Science, 1992. 33(1): p. 1-17. 
139. Friedman, D.S., et al., Racial differences in the prevalence of age-related macular degeneration. Ophthalmology. 
106(6): p. 1049-1055. 
140. Vingerling, J.R., et al., The Prevalence of Age-related Maculopathy in the Rotterdam Study. Ophthalmology. 102(2): 
p. 205-210. 
141. The Eye Diseases Prevalence Research, G., Prevalence of age-related macular degeneration in the united states. 
Archives of Ophthalmology, 2004. 122(4): p. 564-572. 
142. Anderson, D.H., et al., &KDUDFWHUL]DWLRQRI¯DP\ORLGDVVHPEOLHV LQGUXVHQ WKHGHSRVLWVDVVRFLDWHG with aging 
and age-related macular degeneration. Experimental Eye Research, 2004. 78(2): p. 243-256. 
143. Ethen, C.M., et al., Transformation of the proteasome with age-related macular degeneration. FEBS Letters, 2007. 
581(5): p. 885-890. 
144. Johnson, L.V., et al., Complement Activation and Inflammatory Processes in Drusen Formation and Age Related 
Macular Degeneration. Experimental Eye Research, 2001. 73(6): p. 887-896. 
145. Kang, M.-J. and H.D. Ryoo, Suppression of retinal degeneration in Drosophila by stimulation of ER-associated 
degradation. Proceedings of the National Academy of Sciences, 2009. 106(40): p. 17043-17048. 
146. Kroeger, H., et al., Induction of Endoplasmic Reticulum Stress Genes, BiP and Chop, in Genetic and Environmental 
Models of Retinal Degeneration. Investigative Ophthalmology & Visual Science, 2012. 53(12): p. 7590-7599. 
147. Mendes, C.s.S., et al., ER stress protects from retinal degeneration. The EMBO Journal, 2009. 28(9): p. 1296-1307. 
148. Ramos de Carvalho, J.E., et al., Complement Factor C3a Alters Proteasome Function in Human RPE Cells and in 
an Animal Model of Age-Related RPE Degeneration. Investigative Ophthalmology & Visual Science, 2013. 54(10): 
p. 6489-6501. 
149. Ryoo, H.D., et al., Unfolded protein response in a Drosophila model for retinal degeneration. The EMBO Journal, 
2006. 26(1): p. 242-252. 
150. Shimazawa, M., et al., Involvement of ER stress in retinal cell death. Molecular Vision, 2007. 13: p. 578-587. 
151. Yang, L.-p., et al., Endoplasmic reticulum stress is activated in light-induced retinal degeneration. Journal of 
Neuroscience Research, 2008. 86(4): p. 910-919. 
152. Zhang, X., et al., The Proteasome: A Target of Oxidative Damage in Cultured Human Retina Pigment Epithelial 
Cells. Investigative Ophthalmology & Visual Science, 2008. 49(8): p. 3622-3630. 
153. Ryhänen, T., et al., Crosstalk between Hsp70 molecular chaperone, lysosomes and proteasomes in autophagy-
mediated proteolysis in human retinal pigment epithelial cells. Journal of Cellular and Molecular Medicine, 2009. 
13(9b): p. 3616-3631. 
154. Zhong, Y., et al., X-Box Binding Protein 1 Is Essential for the Anti-Oxidant Defense and Cell Survival in the Retinal 
Pigment Epithelium. PLoS ONE, 2012. 7(6): p. e38616. 
155. Crabb, J.W., et al., Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. 
Proceedings of the National Academy of Sciences, 2002. 99(23): p. 14682-14687. 
  25 
156. Doyle, S.L., et al., NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 
by drusen components. Nat Med, 2012. 18(5): p. 791-798. 
157. Wang, Z.V., et al., Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine 
biosynthetic pathway. Cell, 2014. 156(6): p. 1179-92. 
158. Chouchani, E.T., et al., Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial 
ROS. Nature, 2014. 515(7527): p. 431-5. 
159. Mimura, N., et al., Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in 
multiple myeloma. Blood, 2012. 119(24): p. 5772-81. 
160. Coll, R.C., et al., A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory 
diseases. Nat Med, 2015  21,248±255 
161. Youm, Y.-H., et al., The ketone metabolite [beta]-hydroxybutyrate blocks NLRP3 inflammasome-mediated 
inflammatory disease. Nat Med, 2015 21, 263±269 
  
 
  
  26 
 
  27 
DŽŶŽŐĞŶŝĐƵƚŽŝŶĨůĂŵŵĂƚŽƌǇŝƐĞĂƐĞƐ hWZ ?ĂƵƚŽƉŚĂŐǇ
ƌĞůĂƚĞĚŐĞŶĞ ?Ɛ ?
ŝŶǀŽůǀĞĚ 
hWZ
ĂĐƚŝǀĂƚŝŽŶ 
ĞĨĞĐƚŝǀĞ
ĂƵƚŽƉŚĂŐǇ 
ĞĨĞĐƚŝǀĞ
ƉƌŽƚĞĂƐŽŵĞ 
KǆŝĚĂƚŝǀĞ
ƐƚƌĞƐƐ ?ZK  ^
dE&ƌĞĐĞƉƚŽƌ-ĂůƉŚĂƉĞƌŝŽĚŝĐĨĞǀĞƌ
ƐǇŶĚƌŽŵĞ ?dZW^ ? 
dE&Z^& ? ض ض  ض 
&ĂŵŝůŝĂůDĞĚŝƚĞƌƌĂŶĞĂŶĨĞǀĞƌ ?&D& ? D&s  ض  ض 
^ŝĚĞƌŽďůĂƐƚŝĐĂŶĞŵŝĂǁŝƚŚ
ŝŵŵƵŶŽĚĞĨŝĐŝĞŶĐǇ ?ĨĞǀĞƌƐ ?ĂŶĚ
ĚĞǀĞůŽƉŵĞŶƚĂůĚĞůĂǇ ?^/& ? 
dZEd ? ض   ض 
WƌŽƚĞĂƐŽŵĞĂƐƐŽĐŝĂƚĞĚĂƵƚŽŝŶĨůĂŵŵĂƚŽƌǇ
ƐǇŶĚƌŽŵĞƐ P:DW ?EE^ ?E> ?:^> 
W^D ? ض  ض  
WŽůǇŐĞŶŝĐŵŝǆĞĚŝŶĨůĂŵŵĂƚŽƌǇŝƐĞĂƐĞƐ 
/ŶĨůĂŵŵĂƚŽƌǇďŽǁĞůĚŝƐĞĂƐĞ ?/ ? P,>-
 ? ?ĂƐƐŽĐŝĂƚĞĚĂŶĚƌŽŚŶ ?ƐĚŝƐĞĂƐĞ 
d' ? ?> ض ض  ض 
ƌǇƐƚĂůƌƚŚƌŽƉĂƚŚŝĞƐ P'ŽƵƚĂŶĚĐĂůĐŝƵŵ
ƉǇƌŽƉŚŽƐƉŚĂƚĞĚĞŚǇĚƌĂƚĞ ?WW ? 
  ض  ض 
ZŚĞƵŵĂƚŽŝĚĂƌƚŚƌŝƚŝƐ ?Z ?  ض ض  ض 
ŝƐĞĂƐĞƐǁŝƚŚĂŶŝŶĨůĂŵŵĂƚŽƌǇĐŽŵƉŽŶĞŶƚ 
dǇƉĞ ?ĚŝĂďĞƚĞƐ ?d ? ? /WW ?WW ض ض  ض 
ůǌŚĞŝŵĞƌ ?ƐĚŝƐĞĂƐĞ ? ? WK ?WW ?
D ? ? 
ض ض  ض 
WĂƌŬŝŶƐŽŶ ?ƐĚŝƐĞĂƐĞ ?W ? W^ ? ?W^ ? ?
>ZZ< ? ?^E ?
WĂƌŬŝŶ ?:- ? ?
W/E< ? ?,dZ ? 
ض ض ض ض 
ŵǇŽƚƌŽƉŚŝĐůĂƚĞƌĂůƐĐůĞƌŽƐŝƐ ?>^ ? ^K ? ?dW- ? ? ?
W/ 
ض ض  ض 
,ƵŶƚŝŶŐƚŽŶ ?ƐŚŽƌĞĂ ,dd  ض  ض 
ŐĞ-ƌĞůĂƚĞĚŵĂĐƵůĂƌĚĞŐĞŶĞƌĂƚŝŽŶ
 ?ZD ? 
 ض  ض ض 
DĂůŝŐŶĂŶĐǇ ?Ğ ?Ő ?ŵƵůƚŝƉůĞŵǇĞůŽŵĂ ?  ض ض ض ض 
ĂƌĚŝŽǀĂƐĐƵůĂƌĚŝƐĞĂƐĞƐ  ض ض  ض 
ŚƌŽŶŝĐƉĂŶĐƌĞĂƚŝƚŝƐ  ض   ض 
  28 
 
  
Table 1: Diseases associated with defects in protein homeostasis. For the each disease, the genes and 
protein homeostasis pathways which have been implicated in pathogenesis are listed. 
  
Key: TNFRSF1A: TNF receptor super family, member 1A; MEFV: Familial Mediterranean fever gene; 
TRNT1: tRNA nucleotidyltransferase, CCA-adding 1; JMP: joint contractures, muscle atrophy, microcytic 
anemia, and panniculitis-induced childhood-onset lipodystrophy; NNS: Nakajo-Nishimura syndrome; 
CANDLE:  chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature;  JASL: 
Japanese autoinflammatory syndrome with lipodystrophy; PSMB8: proteasome subunit beta type 8; IAPP: 
islet amyloid polypeptide; APP: amyloid precursor protein; APOE: apolipoprotein E; ADAM10: A 
disintegrin and metalloproteinase domain 10; PS1: preselenin 1  PS2: preselenin 2; LRRK2: leucine rich 
repeat kinase 2; SNCA: synuclein alpha; PARKIN: aka Parkinson protein 2 (PARK2);  PINK: PTEN-
induced putative kinase 1;  DJ-1: oncogene DJ1, aka Parkinson protein 7(PARK7);  HTRA2:  HTRA serine 
peptidase 2; SOD1: superoxidase dismutase 1;  TDP-43: transactive response DNA binding protein 1; PDI: 
protein disulphide isomerase and HTT: huntingtin.   
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Figure Legends 
 
Figure 1. Effects of protein misfolding that can lead to disease. Misfolded proteins are potentially 
highly dangerous and may accumulate leading to cell toxicity or inappropriate/ excessive cell signaling. 
Cells therefore attempt to restore protein homeostasis by activating one or more of 3 major branches of 
the UPR; IRE1a, PERK and/ or ATF6; which regulate genes involved in protein production, degradation 
and/or refolding. Failure of these mechanisms often results in cell apoptosis; however, chronic UPR 
activation may promote pathological innate immune activation and defective autophagy. Key: TRAPS: 
tumour necrosis factor receptor-alpha periodic fever syndrome; IRE1D: Inositol requiring enzyme 1-
alpha; UPR: unfolded protein response; PERK: protein kinase-like endoplasmic reticulum kinase; 
ATF6: activating transcription factor 6; XBP-1: X-box binding protein 1; HLA-B27: human leukocyte 
antigen B27; RA: rheumatoid arthritis.  
 
 
